ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care

Foto: ronaldbonss.com/SMWA
Dresden, 9 January 2026. ROTOP Pharmaka yesterday welcomed Saxony’s State Minister for Economic Affairs, Labour, Energy and Climate Protection, Dirk Panter, during his Radiopharmacy Theme Day in the region. The visit underscored Saxony’s growing importance as a hub for radiopharmaceuticals and for innovative approaches that bring diagnostics and therapy closer together in cancer care.
For many years, ROTOP Pharmaka has been a trusted partner in the reliable supply of nuclear medicine products and is actively contributing its expertise to the ongoing advancement of radiopharmacy. With three production sites, our portfolio includes diagnostic products (cold kits), ready to use patient doses, as well as contract development and manufacturing services (CDMO). A particular focus is placed on theranostic concepts that integrate precise diagnostics with targeted therapy in a single, coordinated approach.
During the visit, Dr. Antje Sterger, Chief Operating Officer (COO), and Dr. Eik Schiller, Chief Scientific Officer (CSO), provided insights into ROTOP Pharmaka’s activities and strategic priorities, highlighting the company’s role in advancing radiopharmacy innovation and ensuring reliable patient supply.
As a founding member of the Radiopharmacy Cluster Dresden nukliD®, which connects science and industry, we work closely with partners to accelerate the translation of innovation into clinical practice and to strengthen sustainable patient care. The State Minister’s visit highlighted that radiopharmacy is not only a key driver of medical progress, but also an important catalyst for value creation, investment, and highly skilled jobs in Saxony.
Ähnliche Beiträge
ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care
January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.
ROTOP featured in VentureCapital Magazine
We are delighted to be featured in the latest
New Milestone: RoTecPSMA® Approved in Switzerland
RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced
